https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
Previous studies have quantified direct inpatient costs of skeletal-related events (SREs); however, costs associated with subsequent post-SRE care have not been examined. We identified two study cohorts using 2011-2015 Medicare 20% sample data patients diagnosed with 1) bone metastases from solid tumors or 2) multiple myeloma (MM), both with SRE-related hospitalization discharge dates January 1, 2011-September 30, 2015. We assessed discharge status and costs from discharge to the earliest of death, end of Medicare enrollment
Like
Comment
Share
